Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.

Automated summary

Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.